Stock Taper 
BullFrog AI Holdings, Inc. is a Gaithersburg-based digital biopharmaceutical company utilizing AI/ML for healthcare data analysis and licensing innovative treatments targeting various human diseases.
bfLEAP is an AI/ML platform licensed from Johns Hopkins that analyzes biomedical data to improve drug discovery, patient segmentation, and clinical trial success for biotech and pharma companies.
Bullfrog AI Holdings, Inc. released its annual letter to shareholders on December 30, 2025, detailing significant advancements in technology, commercial execution, and external validation. The letter highlighted a key commercial collaboration with Sygnature Discovery, expected to generate revenue through 2028, and the launch of its bfPREP AI data-preparation module. This announcement consolidated the company's yearly achievements and outlined its strategic priorities, leading to a notable positive market reaction and increased trading volume.
Bullfrog AI entered a strategic collaboration with Sygnature Discovery, a leading contract research organization (CRO), to market its AI-powered drug development platform to Sygnature's global biopharma clients. This move marks a significant shift in Bullfrog AI's go-to-market strategy, leveraging an established partner's sales infrastructure to drive enterprise adoption and revenue.
Fortrea (NASDAQ: FTRE - Get Free Report) and Bullfrog AI (NASDAQ: BFRG - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Risk and Volatility Fortrea has a beta of
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 DWTX | $1.62 | COMPARE |
 EDSA | $3.96 | COMPARE |
 COCP | $1.14 | COMPARE |
 BFRI | $0.93 | COMPARE |
 TRAW | $0.55 | COMPARE |
 CODX | $1.15 | COMPARE |
 IMRN | $1.09 | COMPARE |
 SCNX | $3.72 | COMPARE |
